Search Results - "Veeraraghavan, Jamunarani"

Towards personalized treatment for early stage HER2-positive breast cancer by Goutsouliak, Kristina, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, De Angelis, Carmine, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel

“…Advances in HER2-targeted therapies have improved the survival of patients with HER2-positive breast cancer. The standard-of-care treatment for localized…”
Get full text

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer by Fu, Xiaoyong, Pereira, Resel, De Angelis, Carmine, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Cataldo, Maria L., Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Gutierrez, Carolina, Chamness, Gary C., Feng, Qin, O’Malley, Bert W., Selenica, Pier, Weigelt, Britta, Reis-Filho, Jorge S., Cohen, Ofir, Wagle, Nikhil, Nardone, Agostina, Jeselsohn, Rinath, Brown, Myles, Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel

“…Forkhead box A1 (FOXA1) is a pioneer factor that facilitates chromatin binding and function of lineage-specific and oncogenic transcription factors…”
Get full text

Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications by Veeraraghavan, Jamunarani, Ma, Jiacheng, Hu, Yiheng, Wang, Xiao-Song

“…Gene fusions have long been considered principally as the oncogenic events of hematologic malignancies, but have recently gained wide attention in solid tumors…”
Get full text

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance by Li, Li, Lin, Ling, Veeraraghavan, Jamunarani, Hu, Yiheng, Wang, Xian, Lee, Sanghoon, Tan, Ying, Schiff, Rachel, Wang, Xiao-Song

“…Endocrine therapy is the most common treatment for estrogen receptor (ER)-positive breast cancer, but its effectiveness is limited by high rates of primary and…”
Get full text

Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers by Kim, Jin-Ah, Tan, Ying, Wang, Xian, Cao, Xixi, Veeraraghavan, Jamunarani, Liang, Yulong, Edwards, Dean P., Huang, Shixia, Pan, Xuewen, Li, Kaiyi, Schiff, Rachel, Wang, Xiao-Song

“…More aggressive and therapy-resistant oestrogen receptor (ER)-positive breast cancers remain a great clinical challenge. Here our integrative genomic analysis…”
Get full text

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer by Fu, Xiaoyong, Pereira, Resel, Liu, Chia-Chia, De Angelis, Carmine, Shea, Martin J., Nanda, Sarmistha, Qin, Lanfang, Mitchell, Tamika, Cataldo, Maria L., Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Giuliano, Mario, Gutierrez, Carolina, Győrffy, Balázs, Trivedi, Meghana V., Cohen, Ofir, Wagle, Nikhil, Nardone, Agostina, Jeselsohn, Rinath, Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel

“…Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, the key mediators of high FOXA1 signaling remain…”
Get full text

Curcumin Regulates Low-Linear Energy Transfer γ-Radiation-Induced NFκB-Dependent Telomerase Activity in Human Neuroblastoma Cells by Aravindan, Natarajan, Ph.D, Veeraraghavan, Jamunarani, M.V.Sc, Madhusoodhanan, Rakhesh, Ph.D, Herman, Terence S., M.D, Natarajan, Mohan, Ph.D

“…Purpose We recently reported that curcumin attenuates ionizing radiation (IR)-induced survival signaling and proliferation in human neuroblastoma cells. Also,…”
Get full text

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models by Veeraraghavan, Jamunarani, Gutierrez, Carolina, Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Giuliano, Mario, Shea, Martin J., Mitchell, Tamika, Wang, Tao, Nanda, Sarmistha, Pereira, Resel, Davis, Robert, Goutsouliak, Kristina, Qin, Lanfang, De Angelis, Carmine, Diala, Irmina, Lalani, Alshad S., Nagi, Chandandeep, Hilsenbeck, Susan G., Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel

“…Lapatinib (L) plus trastuzumab (T), with endocrine therapy for estrogen receptor (ER)+ tumors, but without chemotherapy, yielded meaningful response in HER2+…”
Get full text

Irreversible EGFR inhibitor EKB-569 targets low-LET γ-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma by Aravindan, Natarajan, Thomas, Jr, Charles R, Aravindan, Sheeja, Mohan, Aswathi S, Veeraraghavan, Jamunarani, Natarajan, Mohan

“…EKB-569 (Pelitinib), an irreversible EGFR tyrosine kinase inhibitor has shown potential therapeutic efficiency in solid tumors. However, cell-killing potential…”
Get full text

NFκB activity and transcriptional responses in human breast adenocarcinoma cells after single and fractionated irradiation by Madhusoodhanan, Rakhesh, Natarajan, Mohan Natarajan, Veeraraghavan, Jamunarani, Herman, Terence S., Aravindan, Natarajan

“…Radiotherapy is considered mandatory for breast cancer patients undergoing conservative surgery and for women at high risk of recurrence. However, relapse due…”
Get full text

NFκB Signaling Related Molecular Alterations in Human Neuroblastoma Cells after Fractionated Irradiation by MADHUSOODHANAN, Rakhesh, NATARAJAN, Mohan, VEERARAGHAVAN, Jamunarani, HERMAN, Terence S., JAMGADE, Ambarish, SINGH, Nisha, ARAVINDAN, Natarajan

“…Radiotherapy has been used as an adjunctive local-control modality for high-risk neuroblastoma. However, relapse due to radioresistance affects the success of…”
Get full text

NFkappaB signaling related molecular alterations in human neuroblastoma cells after fractionated irradiation by Madhusoodhanan, Rakhesh, Natarajan, Mohan, Veeraraghavan, Jamunarani, Herman, Terence S, Jamgade, Ambarish, Singh, Nisha, Aravindan, Natarajan

“…Radiotherapy has been used as an adjunctive local-control modality for high-risk neuroblastoma. However, relapse due to radioresistance affects the success of…”
Get full text

Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies by Schiff, Rachel, Veeraraghavan, Jamunarani, Fu, Xiaoyong

“…Abstract Multiple lines of preclinical and clinical evidence suggest a continued, albeit altered, role of estrogen receptor (ER) in endocrine resistance, a…”
Get full text

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade by Prat, Aleix, Pascual, Tomás, De Angelis, Carmine, Gutierrez, Carolina, Llombart-Cussac, Antonio, Wang, Tao, Cortés, Javier, Rexer, Brent, Paré, Laia, Forero, Andres, Wolff, Antonio C, Morales, Serafín, Adamo, Barbara, Brasó-Maristany, Fara, Vidal, Maria, Veeraraghavan, Jamunarani, Krop, Ian, Galván, Patricia, Pavlick, Anne C, Bermejo, Begoña, Izquierdo, Miguel, Rodrik-Outmezguine, Vanessa, Reis-Filho, Jorge S, Hilsenbeck, Susan G, Oliveira, Mafalda, Dieci, Maria Vittoria, Griguolo, Gaia, Fasani, Roberta, Nuciforo, Paolo, Parker, Joel S, Conte, PierFranco, Schiff, Rachel, Guarneri, Valentina, Osborne, C Kent, Rimawi, Mothaffar F

“…Abstract Background Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a…”
Get full text

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer by De Angelis, Carmine, Fu, Xiaoyong, Cataldo, Maria Letizia, Nardone, Agostina, Pereira, Resel, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Sethunath, Vidyalakshmi, Wang, Tao, Hilsenbeck, Susan G, Benelli, Matteo, Migliaccio, Ilenia, Guarducci, Cristina, Malorni, Luca, Litchfield, Lacey M, Liu, Jiangang, Donaldson, Joshua, Selenica, Pier, Brown, David N, Weigelt, Britta, Reis-Filho, Jorge S, Park, Ben H, Hurvitz, Sara A, Slamon, Dennis J, Rimawi, Mothaffar F, Jansen, Valerie M, Jeselsohn, Rinath, Osborne, C Kent, Schiff, Rachel

“…Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) are highly effective against estrogen receptor-positive (ER )/HER2 breast cancer; however,…”
Get full text

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis by Schettini, Francesco, Pascual, Tomás, Conte, Benedetta, Chic, Nuria, Brasó-Maristany, Fara, Galván, Patricia, Martínez, Olga, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Fernández-Martinez, Aranzazu, Rognoni, Carla, Griguolo, Gaia, Guarneri, Valentina, Conte, Pier Franco, Locci, Mariavittoria, Brase, Jan C., Gonzalez-Farre, Blanca, Villagrasa, Patricia, De Placido, Sabino, Schiff, Rachel, Veeraraghavan, Jamunarani, Rimawi, Mothaffar F., Osborne, C. Kent, Pernas, Sonia, Perou, Charles M., Carey, Lisa A., Prat, Aleix

“…•We correlated the breast cancer intrinsic subtypes with pCR in HER2+ disease.•The HER2-E subtype was significantly and consistently associated with pCR after…”
Get full text

Abstract 376: Therapeutic role of ESR1 - CCDC170 gene fusion in breast cancer endocrine resistance by Li, Li, Veeraraghavan, Jamunarani, Hu, Yiheng, Wang, Xian, Tan, Ying, Schiff, Rachel, Wang, Xiaosong

“…Abstract Background: Gene fusions resulting from genomic rearrangements are important drivers for cancer initiation and progression. Estrogen receptor-positive…”
Get full text

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance by Nardone, Agostina, Weir, Hazel, Delpuech, Oona, Brown, Henry, De Angelis, Carmine, Cataldo, Maria Letizia, Fu, Xiaoyong, Shea, Martin J., Mitchell, Tamika, Veeraraghavan, Jamunarani, Nagi, Chandandeep, Pilling, Mark, Rimawi, Mothaffar F., Trivedi, Meghana, Hilsenbeck, Susan G., Chamness, Gary C., Jeselsohn, Rinath, Osborne, C. Kent, Schiff, Rachel

“…Background The oestrogen receptor (ER) is an important therapeutic target in ER-positive (ER+) breast cancer. The selective ER degrader (SERD), fulvestrant, is…”
Get full text

Radiation-triggered Tumor Necrosis Factor (TNF) α-NFκB Cross-signaling Favors Survival Advantage in Human Neuroblastoma Cells by Veeraraghavan, Jamunarani, Natarajan, Mohan, Aravindan, Sheeja, Herman, Terence S., Aravindan, Natarajan

“…Induced radioresistance in the surviving cancer cells after radiotherapy could be associated with clonal selection leading to tumor regrowth at the treatment…”
Get full text

A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4 , Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers by Liu, Chia-Chia, Veeraraghavan, Jamunarani, Tan, Ying, Kim, Jin-Ah, Wang, Xian, Loo, Suet Kee, Lee, Sanghoon, Hu, Yiheng, Wang, Xiao-Song

“…Luminal B breast tumors are more aggressive estrogen receptor-positive (ER ) breast cancers characterized by aggressive clinical behavior and a high risk of…”
Get full text